BRCA Gene Mutation
More women tested for the BRCA genes but no corresponding increase in mastectomy rates
Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.
Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation CarriersJuly 19, 2016
Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.
Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian CancerJune 13, 2016
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.
Prophylactic nipple-sparing mastectomy is as effective at preventing breast cancer as more invasive surgeries, according to a multi-institution study.
The BRCA1 mutation may speed the aging of a woman's ovaries,according to a recent report.
Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.
Among young women diagnosed with breast cancer, frequency of testing 95 percent in 2013
The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.
Young black women with a breast cancer diagnosis at age 50 years or younger have a much higher BRCA mutation frequency than that previously reported among young white women with breast cancer.
In a study reviewing black women under 50 with invasive breast cancer, 12 percent had BRCA1 or BRCA2 mutations.
Research indicates that Angelina Jolie's announcement that she had tested positive for BRCA1 influenced some women's intentions to seek out similar genetic testing.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.
Oophorectomy is linked to a 62% reduction in breast cancer death for women diagnosed with breast cancer that carry a BRCA1 gene mutation.
Researchers have identified mutations that were associated with significantly different risks of breast and ovarian cancers, which may have implications for risk assessment and cancer prevention decision making among carriers of these mutations.
Four major themes characterize the experience of cancer risk management for women who are positive for BRCA genetic mutations.
Magnetic resonance spectroscopy (MRS) shows precancerous breast changes in women with BRCA gene mutationMarch 16, 2015
MRS that incorporates monitoring of biochemical changes in tissue could improve the management of women at risk of breast cancer, according to a new study.
Lipid and metabolite deregulation were seen in breast tissue of women carrying BRCA1/2 mutations.
Prostate cancer patients with hereditary mutations in the BRCA genes do not respond as well to conventional treatment such as surgery and radiotherapy, and they have a lower survival rate than patients who do not have these genetic mutations.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
Reduction in distress, unmet information needs with telephone-based, peer-support program
The Tumor BRACAnalysis CDx companion diagnostic test boosted the detection of cancer-causing BRCA1/2 mutations in women with ovarian cancer by over 40 percent.
A new study found that 72% of women with breast cancer who underwent BRCA testing before surgery and learned they were BRCA positive changed their surgical treatment plans.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|